NPPA directs 3 pharma cos to maintain stock of atleast 2.2 crore tablets of FDC Lopinavir and Ritoavir
New Delhi: The National Pharmaceuticals Pricing Authority (NPPA), Department of Pharmaceuticals directed 3 major manufacturers of the HIV Combo drug Lopinavir & Ritonavir to maintain the adequate stock of Lopinavir & Ritonavir to fight against the corona pandemic. The combination drug has shown efficacy in treatement of coronavirus in certain cases
The order directs three manufacturers of the said drug, namely Mylan, Cipla and Aurobindo to make sure that stock of atleast 2.2 crore tablets are maintained at any point in time
" In pursuance to directions given by Department of Pharmaceuticals, the drug manufacturers of FDC namely `Lopinavir & Ritonavir' (200 Mg+50 Mg.) are hereby directed, in the public interest, in order to deal with the situation arising out of COVID-19, to maintain the stock level of said FDC at least 2.20 Crore tablets at any point of time and also to ensure sufficient availability of the said FDC till further orders. The drug manufacturers will maintain stock of said FDC as indicated against the concerned company's name below," the order added
The order whichwas made by Manjesh Porwal, Dy. Director(Enf.) specifically asked the three manufacturers to maintain atleast the following stock
1) Mylan Laboratories Ltd. (140 Lakhs Tablets),
2) Aurobindo Pharma Ltd. (40 Lakhs Tablets),
3) Cipla Ltd. (40 Lakhs Tablets).
The copy for the same has been submitted to PSO to Secretary (Pharma) (w.r.t. Directions issued dated 19th March 2020), Sr. PPS to Secretary (Health), Director General, ICMR, Sr. PPS to Chairman, NPPA, PPS to JS (Policy), Deptt. of Pharmaceuticals
The Drug Controller General of India has approved "restricted use" of the combination of medications lopinavir and ritonavir which are second-line HIV drugs, for treating those affected by novel coronavirus after the Indian Council of Medical Research (ICMR) sought an emergency approval for the same.
For full details click on the following link: